Clinical Trials Logo

Clinical Trial Summary

The goal of this study is to find markers that may help to predict why some patients who have monoclonal gammopathy of unknown significance (MGUS) or smoldering multiple myeloma (SMM) that have no signs or symptoms of disease (asymptomatic) develop multiple myeloma, while others do not. Studying markers such as age, level of proteins in blood, percent of abnormal blood cells in the bone marrow, genes in the abnormal blood cells, and bone abnormalities may help researchers to validate clinical and genomic predictors for future use in clinical practice.


Clinical Trial Description

PRIMARY OBJECTIVE: I. To determine the rate of progression to multiple myeloma after 3 years of follow up. SECONDARY OBJECTIVES: I. To describe baseline patient characteristics and clinical variables. II. To identify molecular and genetic correlates that may predict for progression to multiple myeloma (MM). OUTLINE: Patients undergo collection of blood samples every 6 months for 3 years. Patients may also undergo a biopsy, x-rays, positron emission tomography (PET)/computed tomography (CT) scans, and/or magnetic resonance imaging (MRI) scans to check the status of disease at the discretion of the treating physician. After completion of 3 years on study, patients are followed up every 6-12 months thereafter. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02726750
Study type Observational
Source M.D. Anderson Cancer Center
Contact Mei Huang
Phone 713-745-9901
Email mhuang3@mdanderson.org
Status Recruiting
Phase
Start date December 14, 2015
Completion date April 30, 2026

See also
  Status Clinical Trial Phase
Not yet recruiting NCT05969821 - Clonal Hematopoiesis of Immunological Significance
Not yet recruiting NCT04702932 - Establishment of Genomic, Transcriptomic and Functional Characteristics of Tumor Cells in Hyperinflammatory Hemopathies
Active, not recruiting NCT03327597 - Iceland Screens, Treats or Prevents Multiple Myeloma N/A
Completed NCT01588015 - Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant Phase 1
Completed NCT04439006 - Ibrutinib for the Treatment of COVID-19 in Patients Requiring Hospitalization Phase 1
Completed NCT01955395 - Genomic and Psychosocial Effects of the 3RP on Patients With MGUS and Smoldering Multiple Myeloma N/A
Completed NCT01219010 - A Study Evaluating the Effects of Siltuximab on the Heart in Patients With Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma, or Indolent Multiple Myeloma Phase 1
Completed NCT01237054 - Imaging in MGUS, SMM and MM Phase 2
Active, not recruiting NCT03855878 - Observation of the Incidence and Natural History of MGUS in Patients Undergoing Weight Reduction Surgery
Recruiting NCT05640843 - A Study Comparing a Plant-Based Diet With Supplements and Placebo in People With Monoclonal Gammopathy of Undetermined Significance (MGUS) or Smoldering Multiple Myeloma (SMM) N/A
Completed NCT00099047 - Celecoxib in Preventing Multiple Myeloma in Patients With Monoclonal Gammopathy or Smoldering Myeloma Phase 2
Completed NCT00919139 - S0309, Repository: Blood/Bone Marrow From Pts. With Myeloma, WM, Amyloidosis, or MGUS. N/A
Not yet recruiting NCT05114109 - Isatuximab in Type I Cryoglobulinemia Phase 2
Recruiting NCT04114084 - Sleep Apnea in Patients With MGUS and MM
Recruiting NCT06383143 - Promoting Diagnosis and Management of AL in Italy (ProDigALIty)
Withdrawn NCT01571726 - Imaging Studies and the Development of Multiple Myeloma Phase 2
Recruiting NCT01408225 - Ohio State University Multiple Myeloma and Amyloidosis Data Registry and Sample Resource
Recruiting NCT05136807 - Quality of Life in Patients With Asymptomatic Monoclonal Gammopathies
Active, not recruiting NCT04920084 - A Study of a Plant-Based Diet in People With Monoclonal Gammopathy of Undetermined Significance (MGUS) or Smoldering Multiple Myeloma (SMM) N/A
Recruiting NCT06046287 - Daratumumab for Polyneuropathy Associated With MGUS Phase 2